Teduglutide (GLP2 2G) HGDGSFSDEMNTILDNLAARDFINWLIQTKITD-acid
GLP-2 analogue, resistant to peptidase degradation. Enhanced biological activity relative to native GLP-2
|Sequence (one letter code)||HGDGSFSDEMNTILDNLAARDFINWLIQTKITD-acid|
|Sequence (three letter code)||H-His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-OH|
Jeppesen (2012) Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome. Ther. Adv. Gastroenterol. 5(3) 159 PMID: 22570676
Schwartz et al (2016) Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome. Clin.Transl. Gastroenterol. 7(2) e142 PMID: 26844839
Teduglutide is a GLP-2 analogue, in which the alanine at position 2 has been substituted with glycine making the peptide resistant to degradation by dipeptidyl peptidase-4 (DPP-4); Teduglutide therefore has a longer half-life than GLP-2 (2-3 hours for teduglutide vs 7 min for GLP-2). Teduglutide has high bioavailability after subcutaneous administration, suggesting that teduglutide has enhanced biological activity, relative to native GLP-2.
GLP-2 is a gut hormone produced in the enteroendocrine L cells of gastrointestinal tract by the cleavage of the 160-amino-acid proglucagon molecule. GLP-2 is secreted following the ingestion of food and carries out its activities via the GLP-2 G-protein coupled receptors (GLP-2Rs). GLP-2 has a range of roles within the cell, including: anti-inflammatory effects; promoting the expansion of the intestinal mucosa; stimulating intestinal blood flow; inhibiting gastric acid secretion and gastric emptying; increasing intestinal barrier function and enhancing nutrient and fluid absorption.